DBV.PA

DBV Technologies S.A.

DBV.PA, France

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

https://www.dbv-technologies.com

Stock Price

€0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
DBV.PA
stock
DBV.PA

DBV.PA DBV Technologies (EURONEXT) up 20.84% intraday: volume spike signals follow-through Meyka

Read more →
DBV.PA
stock
DBV.PA

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing Yahoo Finance UK

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

$

Analyst Picks

Strong Buy

0

Buy

1

Hold

1

Sell

1

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

5.56

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-62.47 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-29.88 %

Low 2%

High 10%

Debt to Equity

-

Very Low

1.09

Low 1

High 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of DBV Technologies S.A.

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1

Latest Release

Date

2025-09-30

EPS Actual

-0.1

EPS Estimate

-0.21

EPS Difference

0.11

Surprise Percent

52.381%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

0

Short Term Investments

0

Receivables

0

Inventories

0

Total Current Assets

0

Property Plant Equipment

0

Total Assets

0

Payables

0

Short Term Debt

0

Long Term Debt

0

Total Liabilities

0

Equity

0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

0

Depreciation

0

Change In Working Capital

0

Cash From Operations

0

Capital Expenditures

0

Cash From Investing

0

Cash From Financing

0

Net Change In Cash

0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.